In vivo measurement of glucose and insulin levels are the gold standard for testing your antidiabetic compound efficacy. At CrownBio we can assess the level of circulating sugar or insulin in rodent studies via:
At CrownBio we understand the need to maintain consistency with historical study data, therefore we can run your study with any commercially available rat or mouse model including rodent models of Type 2 diabetes (T2D) with monogenic mutations:
Our Cardiovascular and Metabolic Disease (CVMD) Translational Technology Platform also provides our highly translatable, proprietary models of T2D:
The MS-NASH (formerly called FATZO) mouse and ZDSD rat are polygenic models of dysmetabolism, spontaneously developing metabolic syndrome, obesity, and diabetes, which more closely mimic the human condition than models with leptin/leptin receptor mutations. Both models respond to antidiabetic treatments, providing highly translatable models for efficacy evaluations.
Male MS-NASH mice become hyperglycemic at 14 weeks of age, and also develop insulin resistance at an early age.
The ZDSD rat progresses through T2D similarly to humans, with a bona fide prediabetic state occurring at 8-16 weeks of age. The model develops overt diabetes from 16 weeks of age and diabetic complications from 24 weeks of age.
We also provide models of Type 1 diabetes such as:
At CrownBio we also routinely run a variety of in vitro assays including the evaluation of glucose stimulated insulin secretion on isolated primary islets from various rodent models.